Deciphera Pharmaceuticals, Inc.

Equities

DCPH

US24344T1016

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 03:37:05 2024-03-28 pm EDT 5-day change 1st Jan Change
15.86 USD +4.51% Intraday chart for Deciphera Pharmaceuticals, Inc. +3.06% -0.96%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Deciphera Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:00 AM
Deciphera Pharmaceuticals' Q4 Net Loss Narrows, Revenue Rises MT
Transcript : Deciphera Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 06, 2024
Earnings Flash (DCPH) DECIPHERA PHARMACEUTICALS Posts Q4 Revenue $48.3M, vs. Street Est of $46.8M MT
Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Rate Doubts Keep -2- DJ
Deciphera Says Long-Term Data Show 'Similar' Overall Survival Rates for Qinlock, Sunitinib MT
Deciphera Pharmaceuticals Partners With Genesis Pharma to Distribute Cancer Drug in 14 European Countries MT
GENESIS Pharma and Deciphera Pharmaceuticals, Inc. Announce an Exclusive Distribution Agreement for RIPRETINIB in 14 European Markets in Central and Eastern Europe CI
Transcript : Deciphera Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 04:30 PM
Deciphera Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18 CI
North American Morning Briefing : Fed Decision, -2- DJ
Deciphera Pharmaceuticals Insider Sold Shares Worth $259,256, According to a Recent SEC Filing MT
HC Wainwright Adjusts Deciphera Pharmaceuticals' Price Target to $30 From $25, Keeps Buy Rating MT
JonesTrading Upgrades Deciphera Pharmaceuticals to Buy From Hold, $16 Price Target MT
North American Morning Briefing : Lower Treasury -2- DJ
Piper Sandler Upgrades Deciphera Pharmaceuticals to Overweight From Neutral, Raises Price Target to $23 From $18 MT
Deciphera Pharmaceuticals' Q3 Net Loss Widens, Revenue Rises; Says Phase 3 Tumor Drug Trial Met Primary Endpoint MT
Transcript : Deciphera Pharmaceuticals, Inc., Q3 2023 Earnings Call, Oct 30, 2023
Earnings Flash (DCPH) DECIPHERA PHARMACEUTICALS Posts Q3 Revenue $43.3M MT
Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Deciphera Pharmaceuticals, Inc. Announces Positive Top-Line Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor CI
North American Morning Briefing : Stock Futures -2- DJ
Chart Deciphera Pharmaceuticals, Inc.
More charts
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer. The Company is leveraging its switch-control kinase inhibitor platform in kinase biology to develop a portfolio of medicines. The Company's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition to QINLOCK, it has developed a robust pipeline of drug candidates using its switch-control kinase inhibitor platform, including vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly-selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) kinase for the potential treatment of tenosynovial giant cell tumor (TGCT). DCC-3116 is a Phase 1/2 inhibitor of ULK kinases being developed to inhibit autophagy.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
15.18 USD
Average target price
24.2 USD
Spread / Average Target
+59.42%
Consensus
  1. Stock
  2. Equities
  3. Stock Deciphera Pharmaceuticals, Inc. - Nasdaq
  4. News Deciphera Pharmaceuticals, Inc.
  5. JPMorgan Adjusts Price Target on Deciphera Pharmaceuticals to $10 From $43, Maintains Neutral Rating